The companies are developing a rapid, at-home colorectal cancer test that uses interstitial fluid as a sample type.

The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

The firm reported growth across its immunodiagnostics and molecular diagnostics businesses as well as contributions from the firm's licensed technologies business.